{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:55:14Z","timestamp":1791078914552,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ad.2023.12.007","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T21:40:35Z","timestamp":1708638035000},"page":"547-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas"],"prefix":"10.1016","volume":"115","author":[{"given":"R.","family":"Izu-Belloso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gainza-Apraiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ortiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Servitje-Bedate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fern\u00e1ndez de Misa-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Pe\u00f1ate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hernandez-Machin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Estrach-Panella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Llamas-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.I.","family":"Yanguas-Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Morillo-Andujar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Acebo-Mari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Perez-Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Armario-Hita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sanchez-Sambucety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ortiz-Brugues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Eguren-Michelena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bielsa-Marsol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lopez-Pesta\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Blanes-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fernandez-Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Lopez-Lerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2023.12.007_bib0125","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ad.2023.12.007_bib0130","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-07-202895","article-title":"How I treat mycosis fungoides and sezary syndrome","volume":"114","author":"Prince","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ad.2023.12.007_bib0135","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ad.2023.12.007_bib0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ad.2023.12.007_bib0145","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.12.007_bib0150","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2023.12.007_bib0155","unstructured":"European Medicines Agency. Targretin: summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/targretin."},{"key":"10.1016\/j.ad.2023.12.007_bib0160","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1111\/j.1600-0625.2009.00995.x","article-title":"About the cutaneous targets of bexarotene in CTCL patients","volume":"19","author":"Knol","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ad.2023.12.007_bib0165","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2023.12.007_bib0170","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\u2013III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2023.12.007_bib0175","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1365-2141.2009.07596.x","article-title":"Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids","volume":"145","author":"Musolino","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ad.2023.12.007_bib0180","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and Sezary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.12.007_bib0185","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2340\/00015555-1359","article-title":"Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland","volume":"92","author":"V\u00e4kev\u00e4","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.12.007_bib0190","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1517\/14656566.2013.810718","article-title":"Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature","volume":"14","author":"Qu\u00e9reux","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ad.2023.12.007_bib0195","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1097\/MJT.0000000000000056","article-title":"Polish lymphoma research group experience with bexarotene in the treatment of cutaneous T-cell lymphoma","volume":"23","author":"Sokolowska-Wojdylo","year":"2016","journal-title":"Am J Ther"},{"key":"10.1016\/j.ad.2023.12.007_bib0200","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/1346-8138.15322","article-title":"Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy","volume":"47","author":"Fujimura","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2023.12.007_bib0205","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/1346-8138.16201","article-title":"Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: real-world experience from post-marketing surveillance","volume":"49","author":"Hamada","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2023.12.007_bib0210","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2133.2012.11156.x","article-title":"Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)","volume":"167","author":"Whittaker","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.12.007_bib0215","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjd.12042","article-title":"U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma","volume":"168","author":"Scarisbrick","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.12.007_bib0220","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.2006.07329.x","article-title":"Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion","volume":"155","author":"Assaf","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.12.007_bib0225","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1743-6109.2009.01698.x","article-title":"The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction","volume":"7","author":"Corona","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.ad.2023.12.007_bib0230","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1741-7015-11-57","article-title":"The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Schooling","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.ad.2023.12.007_bib0235","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4103\/1008-682X.123678","article-title":"The role of statins in erectile dysfunction: a systematic review and meta-analysis","volume":"16","author":"Cai","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.ad.2023.12.007_bib0240","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024001601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024001601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:31:52Z","timestamp":1717201912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731024001601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0001731024001601"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2023.12.007","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}